10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2018 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
Revenues | $ 22,561 | 20,776 | 19,427 |
Cost of Goods and Services Sold | 6,547 | 6,094 | 4,969 |
Marketing, selling and administrative | 4,551 | 4,751 | 4,979 |
Research and development | 6,345 | 6,482 | 5,012 |
Other income (net) | (850) | (1,682) | (1,448) |
Total Expenses | 16,593 | 15,645 | 13,512 |
Earnings Before Income Taxes | 5,968 | 5,131 | 5,915 |
Provision for Income Taxes | 1,021 | 4,156 | 1,408 |
Net Earnings | 4,947 | 975 | 4,507 |
Net Income (Loss) Attributable to Noncontrolling Interest | 27 | (32) | 50 |
Net Earnings Attributable to BMS | 4,920 | 1,007 | 4,457 |
Earnings per Common Share | |||
Basic Earnings Per Common Share Attributable to BMS | 3.01 | 0.61 | 2.67 |
Diluted Earnings per Common Share Attributable to BMS | 3.01 | 0.61 | 2.65 |
Principal Transaction Revenue, Description of Reporting Category | |||
Sales Revenue, Net | |||
Revenues | 21,581 | 19,258 | 17,702 |
Alliance and other revenues | |||
Revenues | 980 | 1,518 | 1,725 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2018 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] | |||
Net Earnings | $ 4,947 | 975 | 4,507 |
Other Comprehensive Income (Loss), net of taxes and reclassifications to earnings [Abstract] | |||
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax | 70 | (57) | 4 |
Pension and postretirement benefits | 53 | 214 | (17) |
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax | (25) | 39 | 16 |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | (254) | 18 | (38) |
Other Comprehensive Income (Loss), Net of Tax | (156) | 214 | (35) |
Comprehensive Income | 4,791 | 1,189 | 4,472 |
Comprehensive Income Attributable to Noncontrolling Interest | 27 | (32) | 50 |
Comprehensive Income Attributable to BMS | 4,764 | 1,221 | 4,422 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2018 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
Cash Flows From Operating Activities: | |||
Net Earnings | $ 4,947 | 975 | 4,507 |
Net Cash Provided by Operating Activities | 5,940 | 5,275 | 3,058 |
Adjustments to reconcile net earnings to net cash provided by operating activities: | |||
Depreciation and amortization, net | 637 | 789 | 382 |
Deferred income taxes | 86 | 1,010 | (204) |
Stock-based compensation | 221 | 199 | 205 |
Impairment charges | 126 | 327 | 63 |
Pension settlements and amortization | 186 | 236 | 169 |
Divestiture gains and royalties | (992) | (706) | (1,187) |
Asset acquisition charges | 85 | 760 | 274 |
Loss/(gain) on equity investments | 512 | (23) | 37 |
Other adjustments | (44) | 120 | (36) |
Changes in operating assets and liabilities: | |||
Receivables | (429) | (431) | (803) |
Inventories | (216) | (29) | (152) |
Accounts payable | (59) | 320 | 104 |
Deferred income | 84 | (642) | (64) |
Income taxes payable | 162 | 2,597 | (453) |
Other | 634 | (227) | 216 |
Cash Flows From Investing Activities: | |||
Sale and maturities of marketable securities | 2,379 | 6,412 | 4,809 |
Purchase of marketable securities | (2,305) | (5,437) | (3,089) |
Capital expenditures | (951) | (1,055) | (1,215) |
Divestiture and other proceeds | 1,249 | 722 | 1,334 |
Acquisition and other payments | (1,246) | (708) | (359) |
Net Cash Provided by/(Used in) Investing Activities | (874) | (66) | 1,480 |
Cash Flows From Financing Activities: | |||
Short-term borrowings, net | (543) | 727 | 125 |
Issuance of long-term debt | 0 | 1,488 | 0 |
Repayment of long-term debt | (5) | (1,224) | (15) |
Repurchase of common stock | (320) | (2,469) | (231) |
Dividends | (2,613) | (2,577) | (2,547) |
Other | (54) | (22) | 15 |
Net Cash Used in Financing Activities | (3,535) | (4,077) | (2,653) |
Effect of Exchange Rates on Cash and Cash Equivalents | (41) | 52 | (33) |
Increase/(Decrease) in Cash and Cash Equivalents | 1,490 | 1,184 | 1,852 |
Cash and Cash Equivalents at Beginning of Year | 5,421 | 4,237 | |
Cash and Cash Equivalents at End of Year | 6,911 | 5,421 | 4,237 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2018 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 25, 2019) | ||
(In Millions, except shares in actual) | ||
As of | As of | |
Dec 31, 2018 | Dec 31, 2017 | |
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | $ 6,911 | 5,421 |
Marketable securities, current | 1,973 | 1,391 |
Receivables | 5,965 | 6,300 |
Inventories | 1,195 | 1,166 |
Prepaid expenses and other | 1,116 | 576 |
Total Current Assets | 17,160 | 14,854 |
Property, plant and equipment | 5,027 | 5,001 |
Goodwill | 6,538 | 6,863 |
Other intangible assets | 1,091 | 1,210 |
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | 1,371 | 1,610 |
Marketable securities, noncurrent | 1,775 | 2,480 |
Other Assets, Noncurrent | 2,024 | 1,533 |
Total Assets | 34,986 | 33,551 |
LIABILITIES | ||
Current Liabilities: | ||
Short-term debt obligations | 1,703 | 987 |
Accounts payable | 1,892 | 2,248 |
Accrued liabilities | 6,489 | 6,014 |
Deferred income, current | 172 | 83 |
Income taxes payable, current | 398 | 231 |
Total Current Liabilities | 10,654 | 9,563 |
Deferred income, noncurrent | 468 | 454 |
Income taxes payable, noncurrent | 3,043 | 3,548 |
Pension and other liabilities | 1,048 | 1,164 |
Long-term debt, excluding current maturities | 5,646 | 6,975 |
Total Liabilities | 20,859 | 21,704 |
Commitments and contingencies | ||
EQUITY | ||
Bristol-Myers Squibb Company Shareholders' Equity: | ||
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,070 in 2017 and 4,129 in 2016, liquidation value of $50 per share | 0 | 0 |
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2017 and 2016 | 221 | 221 |
Capital in excess of par value of stock | 2,081 | 1,898 |
Accumulated other comprehensive loss | (2,762) | (2,289) |
Retained earnings | 34,065 | 31,160 |
Less cost of treasury stock - 575 million common shares in 2017 and 536 million in 2016 | (19,574) | (19,249) |
Total Bristol-Myers Squibb Company Shareholders' Equity | 14,031 | 11,741 |
Noncontrolling interest | 96 | 106 |
Total Equity | 14,127 | 11,847 |
Total Liabilities and Equity | 34,986 | 33,551 |
External Links | |
BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2018 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |